Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  fazarabine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-23 of 23 for your search:
Start Over
Phase II Study of Fazarabine and Filgrastim (G-CSF) in Chemotherapy Naive Patients with Recurrent or Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 08/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-964351, NCCTG-96-43-51
Phase II Trial of Fazarabine in Patients with Refractory Metastatic and/or Unresectable Cancers of the Breast, Colon, and Testis (Summary Last Modified 11/91)
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-89-C-105, NCI-MB-241, NCI-T89-0045N, T89-0045
Phase II Study of Fazarabine in Patients with Persistent or Recurrent Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 01/90)
Phase: Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: SWOG-8912
Phase II Study of Fazarabine in Patients with Metastatic Breast Cancer (Summary Last Modified 10/89)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: MDA-DM-89052, NCI-T89-0122C, T89-0122
Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fazarabine (Summary Last Modified 07/90)
Phase: Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: GOG-26GG
Phase II Study of Fazarabine in Patients with Advanced Measurable Colorectal Cancer (Summary Last Modified 06/97)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: MDA-DM-89107, NCI-T89-0212C, T89-0212
Phase II Trial of Fazarabine in Patients with Metastatic Pancreatic or Periampullary Adenocarcinoma (Summary Last Modified 07/90)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-90007, NCI-T90-0021C, T90-0021
Phase II Study of Fazarabine in Patients with CNS Tumors (Summary Last Modified 08/90)
Phase: Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: SWOG-8834
Phase II Study of Intravenous Fazarabine in Patients with Advanced non-Small Cell Lung Cancer (Summary Last Modified 10/91)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-902401, NCI-T90-0062C, T90-0062
Phase II Study of Fazarabine in Children with Recurrent Solid Tumors (Summary Last Modified 08/91)
Phase: Phase II
Type: Treatment
Status: Closed
Age: under 21 at diagnosis
Sponsor: NCI
Protocol IDs: CCG-0902
Phase II Study of ARA-AC in Patients with Advanced Stage IV Nonsmall Cell Lung Carcinoma (Summary Last Modified 09/92)
Phase: Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: SWOG-9138
Phase II Study of Fazarabine in Patients with Poor-Prognosis Extensive Stage Small Cell Lung Cancer (Summary Last Modified 07/93)
Phase: Phase II
Type: Treatment
Status: Completed
Age: adult
Sponsor: NCI
Protocol IDs: SWOG-9213
Phase I Study of ARA-AC/G-CSF for Advanced Cancer (Summary Last Modified 06/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-930101, NCI-T93-0155D, T93-0155
Phase I Chemotherapy with Arabinosyl-5-Azacytidine in Patients with Solid Tumors or Lymphoma
Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: MDA-DM-87002, NCI-T87-0023C, T87-0023
Phase I Study of 1-B-D-Arabinofuranosyl-5-Azacytidine in Patients with Malignancies
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-87-C-24C, NCI-T86-0256N, T86-0256
Phase I Chemotherapy with Fazarabine in Patients with Advanced Refractory Malignancies (Summary Last Modified 11/89)
Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: OSU-87HO050, NCI-T87-0010C, T87-0010
Phase I Study of Arabinosyl-5-Azacytidine in Pediatric Patients with Solid Tumors or Leukemia (Summary Last Modified 06/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: under 21
Sponsor: NCI
Protocol IDs: NCI-87-C-127A, NCI-T87-0200N, T87-0200
Phase I Study of Fazarabine Administered as a 24-Hour Continuous Infusion in Patients with Advanced Malignancies (Summary Last Modified 11/89)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: WCCC-CO-8893, NCI-T88-0099C, T88-0099
Phase I Trial of Fazarabine (Ara-AC) in Patients with Adult Acute Leukemia and CML in Blast Crisis (Summary Last Modified 09/90)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: NCI
Protocol IDs: MDA-DM-88051, NCI-T88-0112C, T88-0112
Phase I Study of Fazarabine in Patients with Refractory Acute Leukemia or CML in Accelerated Phase (Summary Last Modified 03/89)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-88HO312, NCI-T88-0222C, T88-0222
Phase I Study of Prolonged Infusions of ARA-AC Alone and with G-CSF in Pediatric Patients with Relapsed or Refractory Leukemia or Lymphoma (Summary Last Modified 09/94)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: NCI
Protocol IDs: MSKCC-88144A6, NCI-T88-0262D, T88-0262
Phase I Trial of Fazarabine in Children with Refractory Solid Tumors (Summary Last Modified 11/90)
Phase: Phase I
Type: Treatment
Status: Closed
Age: children
Sponsor: NCI
Protocol IDs: POG-8970
Phase I Trial of Fazarabine in Children with Acute Leukemia (Summary Last Modified 11/90)
Phase: Phase I
Type: Treatment
Status: Completed
Age: under 20
Sponsor: NCI
Protocol IDs: POG-9071
Start Over